If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
== Causes == The NIH states: "The causes of most cases of reactive hypoglycemia are still open to debate. Some researchers suggest that certain people may be more sensitive to the body's normal release of the hormone epinephrine, which causes many of the symptoms of hypoglycemia. Others believe deficiencies in glucagon secretion might lead to reactive hypoglycemia. Several other hormones are responsible for modulating the body's response to insulin, including cortisol, growth hormone and sex hormones. Untreated or under-treated hormonal disorders such as adrenal insufficiency (see also Addison's disease) or growth hormone deficiency can therefore sometimes cause insulin hypersensitivity, and reactive hypoglycemia. Stomach bypass surgery or hereditary fructose intolerance are believed to be causes, albeit uncommon, of reactive hypoglycemia. Myo-inositol or 1D-chiro-inositol withdrawal can cause temporary reactive hypoglycemia. There are several kinds of reactive hypoglycemia:
The chemical names were based on the side chains of the compounds. In 1948, Chain introduced the chemical names as standard nomenclature, remarking that this would "make the nomenclature as far as possible unambiguous". In Kundl, Tyrol, Austria, in 1952, Hans Margreiter and Ernst Brandl of Biochemie developed the first acid-stable penicillin for oral administration, penicillin V. American chemist John C. Sheehan at the Massachusetts Institute of Technology (MIT) completed the first chemical synthesis of penicillin V in 1957. Sheehan had started his studies into penicillin synthesis in 1948, and during these investigations developed new methods for the synthesis of peptides, as well as new protecting groups—groups that mask the reactivity of certain functional groups. Although the initial synthesis developed by Sheehan was not appropriate for mass production of penicillins, one of the intermediate compounds in Sheehan's synthesis was 6-aminopenicillanic acid (6-APA), the nucleus of penicillin. An important development was the discovery of 6-APA itself. In 1957, researchers at the Beecham Research Laboratories in Surrey isolated 6-APA from the culture media of P. chrysogenum. 6-APA was found to constitute the core nucleus of penicillin (and subsequently many β-lactam antibiotics) and was easily chemically modified by attaching side chains through chemical reactions. The discovery was published in Nature in 1959. This paved the way for new and improved drugs as all semisynthetic penicillins are produced from chemical manipulation of 6-APA.
Cold Storage is a Singaporean multinational supermarket company. Its parent company also operates Market Place stores, now branded as Cold Storage Fresh, as well as the Giant hypermarket brand, and has various other supermarkets around Asia including Hero and Wellcome. Founded in 1903 as the Singapore Cold Storage Company, Cold Storage was one of the first supermarkets in Singapore to offer its merchandise online in 1997. The number of regular customers has since grown from 6,000 in 1998, to more than 15,000 in 2012. In 1992, DFI purchased the company. It was sold to Macrovalue in 2025. SGS has awarded a HACCP certification to Cold Storage, for its quality and integrity in food safety. As of 2025, Cold Storage operates 45 stores in Singapore across the country.
== Occurrence == PQQ is found in a wide range of food. It is believed that it exists in food as its imidazole and oxazole derivatives. It is found in fruits and vegetables at 7–34 μg/kg, in legume seeds at 18.24 μg/kg, in fermented products at 60–800 μg/kg, in human milk at 140–180 μg/kg, in cow milk at 3.4 μg/kg, and in chicken egg yolk at 7 μg/kg. It is also found in casein, starch, and isolated soy protein at 10–100 μg/kg.
Sources: en.wikipedia.org
=== Structure === The primary structure of renin precursor consists of 406 amino acids with a pre- and a pro-segment carrying 20 and 46 amino acids, respectively. Mature renin contains 340 amino acids and has a mass of 37 kDa.
== Eutectic mixture == Separately, lidocaine and prilocaine are solid bases. When mixed in equal quantities by weight, however, they form a eutectic mixture – that is the melting point of the mixture is lower than the melting points of the individual components. The lidocaine/prilocaine eutectic mixture is an oil with a melting point of 18 °C, and can be formulated into preparations without the use of a non-aqueous solvent. This allows higher concentrations of anaesthetic to be formulated into the preparation and maintained during application.
The two substrates of this enzyme are 2-dehydro-3-deoxy-D-gluconic acid and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are (4S)-4,6-dihydroxy-2,5-dioxohexanoic acid, reduced NADH, and a proton. This enzyme participates in pentose and glucuronate interconversions.
==== Split inteins ==== Sometimes, the intein of the precursor protein comes from two genes. In this case, the intein is said to be a split intein. For example, in cyanobacteria, DnaE, the catalytic subunit α of DNA polymerase III, is encoded by two separate genes, dnaE-n and dnaE-c. The dnaE-n product consists of an N-extein sequence followed by a 123-AA intein sequence, whereas the dnaE-c product consists of a 36-AA intein sequence followed by a C-extein sequence.
Besides modulating electroosmotic flow, capillary wall coatings can also serve the purpose of reducing interactions between "sticky" analytes (such as proteins) and the capillary wall. Such wall-analyte interactions, if severe, manifest as reduced peak efficiency, asymmetric (tailing) peaks, or even complete loss of analyte to the capillary wall.
Sources: en.wikipedia.org
Of the main cast from season 2, only seven returned in leading roles; Zendaya, Schafer, Sweeney, Apatow, Jacob Elordi, Alexa Demie, and Eric Dane. On February 19, 2026, Dane died of ALS after having completed his work on the season. Nika King, who portrayed Leslie Bennett, was demoted to a guest star. Barbie Ferreira, who portrayed Kat Hernandez, announced via Instagram on August 24, 2022 her decision to leave the series. She elaborated in a statement on April 5, 2023: "I just felt like, maybe it's like I overstayed my welcome a little bit. So for me, I actually felt good to be like, 'Okay, I get to not worry about this, and we both don't get too worried about this', because it's exhausting." Storm Reid, who portrayed Gia Bennett, was confirmed to not return in November 2024, with Algee Smith and Austin Abrams, who portrayed Chris McKay and Ethan Daley respectively, departing in February 2025. Javon Walton's character Ashtray died in season 2. Dominic Fike's character Elliot was reported to appear in the season, but did not. Season 2 guest stars Martha Kelly and Chloe Cherry, who portrayed Laurie and Faye Valentine respectively, were promoted to the main cast. Adewale Akinnuoye-Agbaje and Toby Wallace also joined the main cast as Alamo Brown and Wayne. Rosalía, Marshawn "Beast Mode" Lynch, Kadeem Hardison, Darrell Britt-Gibson, Priscilla Delgado, James Landry Hébert, Anna Van Patten, Sharon Stone and Asante Blackk were also announced to have joined the cast in recurring roles.
==== siRNA delivery ==== Short interfering RNA (siRNA) is a powerful new tool that can interfere with and silence the expression of specific disease gene. To improve cellular uptake of siRNA, CPP strategies have been applied to facilitate the delivery of siRNA into cells through either covalent or non-covalent linkages. In one study, siRNA is covalently linked to transportation and penetration by disulfide-linkage at 5'-end of the sense strands of siRNA to target luciferase or eGFP mRNA reporters. In another study, TAT-siRNA conjugate through a stable thiomaleimide linkage at 3'-end of siRNA was delivered into HeLa cells for eGFP gene silencing. However, non-covalent strategies appear to be better for siRNA delivery with a more significant biological response. In one study, MPG/siRNA complexes formed through stable non-covalent strategy showed successful introduction of siRNA into cultured cells and induced robust regulation of target mRNA. Furthermore, MPG/siRNA complexes have also been applied for delivery of siRNA in vivo into mouse blastocytes for gene regulation. MPG forms stable complexes with siRNA with a low degradation rate and can be easily functionalized for specific targeting, which are major advantages compared with the covalent CPP technology.
Jaundice Abnormal liver function test results Tardive dyskinesia – an often incurable movement disorder that usually results from years of continuous treatment with antipsychotic drugs, especially typical antipsychotics like flupenthixol. It presents with repetitive, involuntary, purposeless and slow movements; TD can be triggered by a fast dose reduction in any antipsychotic. Hypotension Confusional state Seizures Mania Hypomania Depression Hot flush Anergia Appetite changes Weight changes Hyperglycemia – high blood glucose (sugar) levels Abnormal glucose tolerance Pruritus – itchiness Rash Dermatitis Photosensitivity – sensitivity to light Oculogyric crisis Accommodation disorder Sleep disorder Impaired concentration Tachycardia QTc interval prolongation – an abnormality in the electrical activity of the heart that can lead to potentially fatal changes in heart rhythm (only in overdose or <10 ms increases in QTc) Torsades de pointes Miosis – constriction of the pupil of the eye Paralytic ileus – paralysis of the bowel muscles leading to severe constipation, inability to pass wind, etc. Mydriasis Glaucoma
=== Royalty litigation === In March 2003, Cambridge Antibody Technology (CAT) stated its wish to "initiate discussions regarding the applicability of the royalty offset provisions for Humira" with Abbott Laboratories in the High Court of London. In November 2004, the trial began, and in December 2004, Justice Hugh Laddie ruled for CAT. A short version of the full statement of the proceedings was released. In it Justice Laddie remarked, "Abbott was in error when it made its first royalty payment to CAT calculated on the basis that only 2% of the Net Sales was due. It should have calculated on the basis of the full royalty of just over 5% and should have paid and continued to pay CAT accordingly." Justice Laddie went on to observe "...that the construction advanced by Abbott does violence to the language of the agreements, renders them obscure and makes little or no commercial sense. For this reason CAT wins the action." Abbott was required to pay CAT US$255 million, some of which was to be passed to its partners in development. Of this sum, the Medical Research Council received US$191 million, and in addition, Abbott was asked to pay the MRC a further US$7.5 million over five years from 2006, providing that Humira remains on the market. The MRC also is to receive a further £5.1 million (sterling) in respect of past royalties.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.